Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Ahmad, Aamir ^a   Maitah, Ma'In Y ^a   Ginnebaugh, Kevin R ^a   Li, Yiwei ^a   Bao, Bin ^a   Gadgeel, Shirish M ^a   Sarkar, Fazlul H ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

EMT; Erlotinib resistance; GDC 0449; Hh signaling; miRNAs; NSCLC

Indexed keywords

CATENIN; CISPLATIN; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; MICRORNA; MICRORNA 200; MICRORNA 200B; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VISMODEGIB;

ARTICLE; CANCER CELL; CANCER STEM CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG SENSITIZATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; HEDGEHOG PROTEINS; HUMANS; LUNG NEOPLASMS; MICRORNAS; PYRIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84885003520     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-77     Document Type: Article

References (37)

1. Cancer statistics, 2013. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2013 63 11 30 10.3322/caac.21166 23335087
2. Annual number of lung cancer deaths potentially avertable by screening in the United States. Ma J, Ward EM, Smith R, Jemal A, Cancer 2013 119 1381 1385 10.1002/cncr.27813 23440730
3. Up-regulation of sonic hedgehog contributes to TGF-beta1-induced epithelial to mesenchymal transition in NSCLC cells. Maitah MY, Ali S, Ahmad A, Gadgeel S, Sarkar FH, PLoS One 2011 6 16068 10.1371/journal.pone.0016068 21249152
4. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W, et al. Cancer Res 2011 71 3400 3409 10.1158/0008-5472.CAN-10-0965 21389093
5. Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis. Gomes LR, Terra LF, Sogayar MC, Labriola L, Curr Pharm Biotechnol 2011 12 11 1881 1890 10.2174/138920111798377102 21470131
6. Genes associated with epithelial-mesenchymal transition: possible therapeutic targets in ductal pancreatic adenocarcinoma? Hotz HG, Hotz B, Buhr HJ, Anticancer Agents Med Chem 2011 11 448 454 10.2174/187152011795677436 21492078
7. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. Bao B, Wang Z, Ali S, Kong D, Banerjee S, Ahmad A, et al. J Cell Biochem 2011 112 2296 2306 10.1002/jcb.23150 21503965
8. Cancer stem cells: perspectives of new therapeutical approaches for breast cancer. Nicolini A, Ferrari PP, Fini MM, Borsari VV, Fallahi PP, Antonelli AA, et al. Front Biosci (Schol Ed) 2011 3 1486 1499 21622284
9. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al. Cancer Res 2005 65 9455 9462 10.1158/0008-5472.CAN-05-1058 16230409 (Pubitemid 41508014)
10. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, et al. Mol Cancer Res 2010 8 1207 1216 10.1158/1541-7786.MCR-10-0052 20696752
11. Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Takeyama Y, Sato M, Horio M, Hase T, Yoshida K, Yokoyama T, et al. Cancer Lett 2010 296 216 224 10.1016/j.canlet.2010.04.008 20452118
12. Erlotinib resistance in lung cancer: current progress and future perspectives. Tang J, Salama R, Gadgeel SM, Sarkar FH, Ahmad A, Front Pharmacol 2013 4 15 23407898
13. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, et al. Cancer Res 2006 66 944 950 10.1158/0008-5472.CAN-05-1988 16424029 (Pubitemid 43165962)
14. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, et al. Clin Cancer Res 2005 11 8686 8698 10.1158/1078-0432.CCR-05-1492 16361555 (Pubitemid 43005918)
15. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, et al. Mod Pathol 2009 22 668 678 10.1038/modpathol.2009.19 19270647
16. Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA. Katoh Y, Katoh M, Int J Mol Med 2008 22 271 275 18698484
17. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, et al. Nature 2003 425 851 856 10.1038/nature02009 14520413 (Pubitemid 37355945)
18. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB, Nature 2003 422 313 317 10.1038/nature01493 12629553 (Pubitemid 36378358)
19. Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Yuan Z, Goetz JA, Singh S, Ogden SK, Petty WJ, Black CC, et al. Oncogene 2007 26 1046 1055 10.1038/sj.onc.1209860 16909105
20. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, et al. Cancer Res 2007 67 2187 2196 10.1158/0008-5472.CAN-06-3281 17332349 (Pubitemid 46424238)
21. Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. Fukaya M, Isohata N, Ohta H, Aoyagi K, Ochiya T, Saeki N, et al. Gastroenterology 2006 131 14 29 10.1053/j.gastro.2006.05.008 16831586 (Pubitemid 44015761)
22. SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-alpha-independent manner. Greer RM, Peyton M, Larsen JE, Girard L, Xie Y, Gazdar AF, et al. Cancer Res 2011 71 7640 7648 10.1158/0008-5472.CAN-10-3947 22049529
23. Selective sensitization of tumors to chemotherapy by marine-derived lipids: a review. Hajjaji N, Bougnoux P, Cancer Treat Rev 2013 39 473 488 10.1016/j.ctrv.2012.07.001 22850619
24. MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. Xiang Q, Tang H, Yu J, Yin J, Yang X, Lei X, Pharmazie 2013 68 274 281 23700794
25. Lithium enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells. Lan Y, Liu X, Zhang R, Wang K, Wang Y, Hua ZC, Biometals 2013 26 241 254 10.1007/s10534-012-9607-x 23378009
26. Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib. Ling YH, Li T, Perez-Soler R, Haigentz M Jr, Cancer Chemother Pharmacol 2009 64 539 548 10.1007/s00280-008-0902-8 19130057
27. Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment. Orzaez M, Guevara T, Sancho M, Perez-Paya E, Cell Death Dis 2012 3 415 10.1038/cddis.2012.155 23096116
28. Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer. Lee JG, Wu R, PLoS One 2012 7 48532 10.1371/journal.pone. 0048532 23119048
29. Silencing of the SNARE protein NAPA sensitizes cancer cells to cisplatin by inducing ERK1/2 signaling, synoviolin ubiquitination and p53 accumulation. Wu ZZ, Sun NK, Chien KY, Chao CC, Biochem Pharmacol 2011 82 1630 1640 10.1016/j.bcp.2011.08.018 21903092
30. Let-7c governs the acquisition of chemo- or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant lung adenocarcinoma. Cui SY, Huang JY, Chen YT, Song HZ, Feng B, Huang GC, et al. Mol Cancer Res 2013 11 699 713 10.1158/1541-7786.MCR-13-0019-T 23562878
31. Are we missing the target? Cancer stem cells and drug resistance in non-small cell lung cancer. Gottschling S, Schnabel PA, Herth FJ, Herpel E, Cancer Genomics Proteomics 2012 9 275 286 22990107
32. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, Ochi N, et al. Cancer Sci 2013 104 78 84 10.1111/cas.12045 23066953
33. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, et al. Stem Cells 2009 27 1712 1721 10.1002/stem.101 19544444
34. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, et al. PLoS One 2012 7 33729 10.1371/journal.pone.0033729 22442719
35. Let-7a elevates p21(WAF1) levels by targeting of NIRF and suppresses the growth of A549 lung cancer cells. He X, Duan C, Chen J, Ou-Yang X, Zhang Z, Li C, et al. FEBS Lett 2009 583 3501 3507 10.1016/j.febslet.2009.10.007 19818775
36. Clinical significance and the correlation of expression between Let-7 and K-ras in non-small cell lung cancer. Xia XM, Jin WY, Shi RZ, Zhang YF, Chen J, Oncol Lett 2010 1 1045 1047 22870110
37. miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, Baird BN, et al. Mol Cancer Res 2011 9 25 35 10.1158/1541-7786.MCR-10-0497 21115742